An open trial of venlafaxine for the treatment of late-life atypical depression

International Journal of Geriatric Psychiatry

Volumn 19, Issue 10, 2004, Pages 989-994

  Roose, Steven P ^a   Miyazaki, Marissa ^a   Devanand, Dev ^a   Seidman, Stuart ^a   Fitzsimmons, Linda ^a   Turret, Nancy ^a   Sackeim, Harold ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Atypical depression; Late life depression; Late onset depression; Major depressive disorder with atypical features; Venlafaxine

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

AGED; ARTICLE; ATYPICAL DEPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; HUMAN; HYPERSOMNIA; INCREASED APPETITE; MALE; NAUSEA; ONSET AGE; OPEN STUDY; PATIENT ATTITUDE; REMISSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGE OF ONSET; AGED; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CYCLOHEXANOLS; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 5744245544     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1201     Document Type: Article

References (16)

1. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders ,4th edn. American Psychiatric Association: Washington, DC.
2. Benazzi F. 2000. Late-life atypical major depressive episode: a 358-case study in outpatients. Am J Geriatr Psychiatry 8: 117-122.
3. First MB, Spitzer B, Gibbon M, Williams JBW. 1997. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P). Biometrics Research Department, New York State Psychiatric Institute.
4. First MB, Spitzer B, Gibbon M, Williams JBW, Lorna B. 1994. Structured Clinical Interview for DSM-IV Axis II Personality Disorders Biometrics Research Department, New York State Psychiatric Institute.
5. Hamilton MW. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-60.
6. Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, Risser RC. 1999. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 56: 431-437.
7. Liebowitz MR, Quitkin FM, Stewart JW, et al. 1984. Phenelzine vs imipramine in atypical depression. Arch Gen Psychiatry 41: 669-677.
8. Liebowitz MR, Quitkin FM, Stewart JW, et al. 1988. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 45: 129-137.
9. Matza L, Revicki D, Davidson J, Stewart J. 2003. Depression with atypical features in the national comorbidity survey. Arch Gen Psych 60: 817-826.
10. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF. 2000. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 157: 344-350.
11. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. 1998. Course and treatment of atypical depression. J Clin Psychiatry 59(Suppl. 18): 5-9.
12. O'Brien J, Ames D, Chiu E, Schweitzer I, Desmond P, Tress B. 1998. Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ 317: 982-984.
13. Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression: evidence-based conclusions. J Clin Psychopharmacol, in press.
14. SPSS Advanced Models 10.0. 2000. SPSS Inc, Prentice Hall.
15. Stewart JW, McGrath PJ, Rabkin JG, Quitkin FM. 1993. Atypical depression: a valid clinical entity? Psychiatr Clin North Am 16 479-495.
16. West ED, Daily PJ. 1959. Effect of Iproniazid in Depressive Syndromes. BMJ 1: 1491-1494.